Discussing Companion Diagnostics with Dr Miguel Quesada-González

You may have heard of Companion Diagnostics. This type of diagnostic provides information that is essential for the safe and effective use of a corresponding drug or biological product. It can help to stratify groups of patients which will respond safely to a clinical drug trial, and those who may suffer undesirable side effects.

But why are Companion Diagnostics useful?

Randox Biosciences Pharma Relationship Manager Dr Miguel Quesada-González, PhD has the answer.

“As part of my new role, I’ll be supporting drug development and clinical trials. So as a scientist by background (the nature of the beast) I’ve been reading into and researching this incredibly interesting area of science.

“Since Day 1, Companion Diagnostics (CDx) especially caught my eye.

“When it comes to new drug development, either for Pharma or Biotech, there are many benefits of running a CDx. Based on well-acknowledged scientific papers that I have read, and my own personal perception of the current situation, I’d like to summarise and simplify in just 2 bullet points, what I personally believe to be the most important benefits of running a CDx.

“(a)  Delivering the right treatment to the right patient at the right time.

“We should never forget that our priority is the health and integrity of patients. It’s been proven that patients who have similar diagnoses very often respond differently to the same treatment. This variability presents a risk in both the efficacy of the treatment and the safety of the patient.

“The development of a drug is already a risky, long and costly process, so wouldn’t you like to avoid the initial high risk by having a good defined target initially?

“(b)  Saving time.

“Money is valuable but time even more so. Time is precious and priceless. Once it’s gone, there’s nothing we can do about it!

“The smaller and more targeted the clinical trials are, the less time and resources you’ll be spending. Normally, the CDx is not initiated until a drug has reached the later stages of development, but, actually, if you put the CDx in place at early development stages (preclinical) it presents many advantages because it enables the selected biomarker to be validated and determined before large amounts of resources have been put in place.

“The faster a potential treatment is developed and approved, the more people you can save, cure or simply improve their quality of life.”

For further information on Companion Diagnostics from Randox Biosciences please email us at info@randoxbiosciences.com

Dr Miguel Quesada-González, PhD, Randox Biosciences Pharma Relationship Manager

 

 

 

 

 


Clinical Laboratory Survey